Long-term Outcomes of Paclitaxel-Eluting Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention: AMeta-Analysis.

@article{Kong2017LongtermOO,
  title={Long-term Outcomes of Paclitaxel-Eluting Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention: AMeta-Analysis.},
  author={Jie Kong and Peng Liu and Xueqiang Fan and Jianyan Wen and Jianbin Zhang and Yanan Zhen and Jinyong Li and Yiyao Cui and Xia Zheng and Zhidong Ye},
  journal={Journal of the College of Physicians and Surgeons--Pakistan : JCPSP},
  year={2017},
  volume={27 7},
  pages={432-439}
}
The relative long-term efficacy and safety of sirolimus-eluting stents (SES) compared with paclitaxel-eluting stents (PES) in multiple comparative studies remains controversial. This report evaluates 29 randomized trials with 18,379 patients in whom long-term (more than 1 year) outcomes were evaluated. The primary outcomes were target lesion revascularization (TLR) and the secondary end points were death, cardiac death, myocardial infarction (MI), major adverse cardiac events (MACEs), target… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…